Promoting rational use of medicines in Europe Posted 25/03/2011
In a report by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute), measures for promoting the rational use of medicines in the 27 EU Member States were surveyed.
Key measures for the rational use of medicines studied by GÖG/ ÖBIG were: Physicians prescribing by the active ingredient name (INN) rather than the brand name. Prescription guidelines ensure that the right medicine at the correct dose is given to the right patient at the right time. When third party payers (sickness funds or national health services) apply this cost-containment measure, the maximum amount of money to be spent on medicines in a specific region or over a period of time is fixed. When pharmacists substitute a brand name medicine for a generic or another cheaper medicine containing the same active ingredient(s). The act of assessing/observing prescribing practices of physicians applied by payers. It is sometimes accompanied by feedback to prescribers. Information activities carried out by payers to convey the reasons for rational drug use, e.g. campaigns to promote generics. In some of the countries surveyed by GÖG/ÖBIG these measures were only indicative, whereas in others they were obligatory, including sanctions for non-compliance in some cases. The series of seven articles that follow present the results obtained by the GÖG/ÖBIG study. Acknowledgement This article is published with permission of the Gesundheit Österreich GmbH (GÖG)/Austrian Health Institute. We gratefully acknowledge the support from Dr Sabine Vogler of Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute) to GaBI Online. Related articles The EU and rational use of medicines Survey on rational use of medicines in 27 EU Members States The Netherlands and rational use of medicines Italy’s rational use of medicines Germany’s rational use of medicines Rational use of medicines in Denmark France’s rational use of medicines Reference Vogler S, Schmickl B. Rational use of medicines in Europe. Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG). February 2010.
Comments (0)
Generics News Research General
- Clopidogrel goes off-patent: last of the old-st...Generics/General | Posted 18/05/2012
- Generic atorvastatin could save NHS GBP 350 mil...Generics/News | Posted 18/05/2012
- Can generic competition succeed at reducing cos...Generics/Research | Posted 11/05/2012
- Also noted on generics: 11 May 2012Generics/General | Posted 11/05/2012
Biosimilars News Research General
- Biosimilars approved and marketed in BelgiumBiosimilars/General | Posted 18/05/2012
- Biosimilar filgrastim provides cost savings for...Biosimilars/Research | Posted 11/05/2012
- US Supreme Court looks set to challenge Afforda...Biosimilars/General | Posted 18/05/2012
- Daiichi Sankyo and Coherus BioSciences make bio...Biosimilars/News | Posted 18/05/2012




